CAJ | 학술논문

目的：探讨化疗对合并2型糖尿病（T2DM）恶性肿瘤患者血清白细胞介素-6（IL-6）水平的影响。方法选择合并T2DM恶性肿瘤患者40例，非合并T2DM恶性肿瘤患者40例，两组患者均给予2个周期化疗，并采集每周期化疗前1 d和化疗结束后第2天空腹静脉血，分离血清，采用酶联免疫吸附法（ ELISA）检测血清IL-6含量，并选取20例健康人群进行对照比较。结果第1周期化疗前合并/非合并T2 DM组IL-6含量均明显高于正常对照组（P＜0．05）。合并T2DM组不同类型肿瘤患者第1周期化疗后血清IL-6含量降低，而第2周期化疗后含量却较第2周期化疗前升高（ P＜0．05）；非合并T2DM组不同类型肿瘤患者第1、2周期化疗后血清IL-6含量呈持续降低趋势（P＜0．05），但两组间比较差异无统计学意义（P＞0．05）。结论第1周期化疗可促进合并/非合并T2DM恶性肿瘤患者血清IL-6表达水平下降；第2周期化疗可继续促进非合并T2DM恶性肿瘤患者血清IL-6表达水平下降，但却同时促进合并T2DM恶性肿瘤患者血清IL-6表达水平回升。
목적：탐토화료대합병2형당뇨병（T2DM）악성종류환자혈청백세포개소-6（IL-6）수평적영향。방법선택합병T2DM악성종류환자40례，비합병T2DM악성종류환자40례，량조환자균급여2개주기화료，병채집매주기화료전1 d화화료결속후제2천공복정맥혈，분리혈청，채용매련면역흡부법（ ELISA）검측혈청IL-6함량，병선취20례건강인군진행대조비교。결과제1주기화료전합병/비합병T2 DM조IL-6함량균명현고우정상대조조（P＜0．05）。합병T2DM조불동류형종류환자제1주기화료후혈청IL-6함량강저，이제2주기화료후함량각교제2주기화료전승고（ P＜0．05）；비합병T2DM조불동류형종류환자제1、2주기화료후혈청IL-6함량정지속강저추세（P＜0．05），단량조간비교차이무통계학의의（P＞0．05）。결론제1주기화료가촉진합병/비합병T2DM악성종류환자혈청IL-6표체수평하강；제2주기화료가계속촉진비합병T2DM악성종류환자혈청IL-6표체수평하강，단각동시촉진합병T2DM악성종류환자혈청IL-6표체수평회승。
Objective To explore the effect of chemotherapy on serum IL-6 expression in cancer patients with T2DM. Methods Eighty patients were divided into the malignant tumor group with T 2DM (n=40) and the malignant tumor group without T2DM (n=40).All the patients were given two cycles of chemotherapy .2 ml of fasting venous blood in the morn-ing before and after the day of chemotherapy was collected .Then the serum was separated .Enzyme-linked immunosorbent assay (ELISA)was used to measure the level changes of serum IL-6.20 cases of healthy people were selected for compari-son.Results The expression of serum IL-6 in groups with or without T2DM was significantly higher than in the normal control group before the first cycle of chemotherapy (P<0.05).The expression of serum IL-6 was decreased in the different-cancer group with T2DM after the first cycle of chemotherapy .But the level was increased after the second cycle of chemo-therapy (P<0.05).The expression of serum IL-6 showed a continuous decrease after the first and the second cycle of chemotherapy in the group without T2DM(P<0.05),but there was no significant difference between the two groups (P>0.05).Conclusion The expression level of serum IL-6 declines after the first cycle chemotherapy in the malignant tumor groups with T2DM or without T2DM but rises in the malignant tumor group with T2DM after the second cycle chemotherapy .